Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5952340	ROCHE	Use of granisetron for the treatment of postoperative nausea and vomiting	Sep, 2016 (7 years ago)

Kytril is owned by Roche.

Kytril contains Granisetron Hydrochloride.

Kytril has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Kytril are:

Kytril was authorised for market use on 17 September, 2004.

Kytril is available in injectable;injection dosage forms.

Kytril can be used as post operative nausea and vomiting.

The generics of Kytril are possible to be released after 14 September, 2016.

Drug Exclusivity	Drug Exclusivity Expiration
M(M-102)	Apr 29, 2014

Market Authorisation Date: 17 September, 2004

Treatment: Post operative nausea and vomiting

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1 mg/mL, 1 mL single dose vial	08 Mar, 2007	1
1 mg/mL, 1 mL vials	01 Jun, 2004	1	31 Dec, 2007	04 May, 2019	Eligible
1 mg/mL, 4 mL multi-dose vials	19 Jul, 2004	1	31 Dec, 2007	04 May, 2019	Eligible

Strength	Dosage	Availability
EQ 3MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 4MG BASE/4ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 1MG BASE/ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued

Kytril patents expiration